Eli Lilly and Co. on Monday announced that its Type 2 diabetes treatment drug Trulicity (dulaglutide) , is now available in U.S. pharmacies. The drug is a once-weekly glucagon-like peptide-1 receptor agonist, and comes in a single-dose pen, which doesn't require the patient to mix, measure or handle the needle, the company said.
Sandoz last week announced the launch of a generic version of cyclophosphamide injection, USP. Sandoz is launching the drug through collaboration with Jiangsu Hengrui Medicine Co., which owns the product's abbreviated new drug application.
Janssen Therapeutics announced earlier this week that the Food and Drug Administration approved Olysio (simeprevir), a hepatitis C virus NS3/4A protease inhibitor, in combination with sofosbuvir as an all-oral, interferon- and ribavirin-free treatment option for genotype 1 chronic hepatitis C (CHC) infection in adult patients as part of a combination antiviral treatment regimen.
Novo Nordisk announced the launch of NovoFine Plus in the United States. NovoFine Plus is a universal needle that works with all currently available insulin, as well as some GLP-1 receptor agonist pens, the company said.
AstraZeneca on Thursday announced that the Food and Drug Administration approved Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily drug for the treatment of adults with Type 2 diabetes.